On this page
Familial isolated pituitary adenoma
FIPA is a rare inherited disorder that leads to an increased risk of specific types of pituitary adenomas, often appearing earlier in life. Understanding its genetic basis is key for family screening and tailored management.
Overview
Familial Isolated Pituitary Adenoma (FIPA) is a rare genetic condition where individuals have an increased chance of developing one or more pituitary adenomas. These adenomas are benign (non-cancerous) growths that develop in the pituitary gland, a small gland located at the base of the brain [PMID:24076371]. While most pituitary tumours occur sporadically, FIPA specifically refers to cases where there is a clear family history of such adenomas, but without the presence of other associated tumour syndromes.
The pituitary gland plays a crucial role in regulating many bodily functions by producing and releasing various hormones. Pituitary adenomas can cause problems either by pressing on surrounding brain structures or by producing too much of a specific hormone. FIPA is classed as a rare disease, meaning it affects a small number of people.
Symptoms & clinical features
The symptoms of FIPA are primarily those associated with pituitary adenomas themselves. These can vary widely depending on the size of the tumour and whether it is overproducing specific hormones. Common symptoms include headaches and visual disturbances, such as tunnel vision or loss of peripheral vision, which occur when the tumour presses on the optic nerves [PMID:27083091].
Hormonal imbalances can lead to a range of symptoms. For instance, an adenoma producing too much growth hormone can result in acromegaly (in adults) or gigantism (in children), characterised by enlarged hands, feet, and facial features. Prolactin-producing adenomas may cause irregular menstrual periods or milk production in women, and reduced libido or erectile dysfunction in men. Other hormonal issues include adrenal insufficiency or hypothyroidism. Often, adenomas in FIPA tend to be larger and develop at a younger age compared to sporadic cases.
Video: Genetics 101
Affected organs
The primary organ affected in FIPA is the pituitary gland, a pea-sized gland situated at the base of the brain, behind the nose. Pituitary adenomas develop from the cells of this gland. Although the adenomas themselves are benign, their location and potential for hormone overproduction mean they can impact various other organ systems. For example, growth hormone-producing tumours can affect bone density, heart function, and metabolic processes, while prolactinomas can influence reproductive organs [PMID:24076371]. The mass effect of larger tumours can also compress nearby brain structures, primarily the optic chiasm, leading to visual problems.
Risks & severity
Individuals with FIPA have a significantly increased lifetime risk of developing pituitary adenomas compared to the general population. These adenomas often present at a younger age, sometimes in adolescence or early adulthood, and can be larger and more aggressive than sporadic forms. The severity of FIPA is variable, even within the same family, and depends on the specific type of adenoma, its size, and how responsive it is to treatment.
Some research suggests that there may be a higher incidence of growth hormone-producing adenomas (somatotrophinomas) in FIPA, leading to conditions like acromegaly or gigantism [PMID:33994273]. While the adenomas are benign, their potential for significant hormonal imbalance and local compression means they can cause considerable health complications if not diagnosed and managed effectively. The exact prevalence of FIPA in the UK population is not well established due to its rarity and the variability in diagnosis.
Genetic causes
Familial Isolated Pituitary Adenoma is most commonly associated with pathogenic variants in the AIP (Aryl Hydrocarbon Receptor Interacting Protein) gene. The AIP gene provides instructions for making a protein that acts as a co-chaperone, meaning it assists other proteins in folding correctly. The AIP protein is thought to play a role in regulating cell growth and division, particularly within hormone-producing cells [PMID:24076371].
When a pathogenic variant occurs in the AIP gene, the AIP protein may not function correctly. This disruption can lead to uncontrolled growth of cells in the pituitary gland, resulting in the formation of an adenoma. This mechanism is still an active area of research, but it is clear that a dysfunctional AIP protein contributes to the development of pituitary tumours in affected individuals.
- AIP AHR interacting HSP90 co-chaperone
Inheritance pattern
FIPA is inherited in an autosomal dominant pattern. This means that a person only needs to inherit one copy of the altered AIP gene from one parent to be at an increased risk of developing the condition. If a parent has a pathogenic variant in the AIP gene, each of their children has a 50% chance (one in two) of inheriting that variant and, therefore, an increased risk of developing FIPA.
not everyone who inherits the altered gene will develop a pituitary adenoma; this is known as reduced penetrance. However, those who do often develop adenomas at a younger age and sometimes with greater severity. Genetic counselling can provide detailed information about inheritance patterns and risks for family members.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
Diagnosis & testing
The diagnosis of FIPA begins with clinical suspicion prompted by a personal or family history of pituitary adenomas, especially if they are aggressive, multiple, or occur at a young age. This is typically followed by hormone level tests and imaging of the pituitary gland, such as an MRI scan, to identify any existing adenomas [PMID:27083091].
Genetic testing is used to confirm a diagnosis of FIPA. This often involves looking for pathogenic variants in the AIP gene, usually through a blood sample. In the UK, such testing is generally accessed through the NHS Genomic Medicine Service (GMS) via referral from a specialist clinic, such as an endocrinology or clinical genetics department. The relevant NHS Genomic Test Directory R-code for familial hypopituitarism (which includes AIP-related conditions) is R143.
Management & lifestyle
Due to the potential for larger and more aggressive tumours, management of FIPA often involves regular monitoring for adenoma development. This typically includes periodic hormone level assessments and MRI scans of the pituitary gland, particularly for individuals in affected families who carry an AIP gene variant. Treatment for pituitary adenomas depends on the tumour's size, its hormonal activity, and its impact on the patient [PMID:27083091].
Options may include pharmacological treatments to reduce hormone production or tumour size, surgery to remove the adenoma, or radiotherapy. The specific approach is determined by a multidisciplinary team of specialists, including endocrinologists, neurosurgeons, and oncologists. Genetic counselling is a vital part of the management pathway for FIPA, providing crucial information and support to affected individuals and their families regarding screening, surveillance, and reproductive options.
UK care pathway
In the UK, individuals suspected of having FIPA, or those with a family history, are typically referred to specialist endocrinology centres or clinical genetics services. These services are part of the NHS Genomic Medicine Service (GMS) and can provide access to genetic testing and counselling. Genetic testing for FIPA is listed in the NHS Genomic Test Directory under R-codes such as R143 (for familial pituitary adenoma).
Clinical geneticists and genetic counsellors play a key role in explaining the inheritance pattern, discussing the implications for family members, and coordinating cascade testing within families. These pathways ensure that individuals receive comprehensive care, from diagnosis and surveillance to treatment and psychological support.
Frequently asked questions
What is the pituitary gland?
The pituitary gland is a small, pea-sized gland located at the base of your brain. It is sometimes called the 'master gland' because it produces and releases many hormones that control other glands and bodily functions, including growth, metabolism, and reproduction.
Are pituitary adenomas always cancerous?
No, pituitary adenomas are almost always benign, meaning they are non-cancerous growths. However, even though they are not cancerous, they can still cause health problems by producing too much hormone or by pressing on nearby brain structures, such as the nerves that control vision.
If someone in my family has FIPA, should I be tested?
If a close relative has been diagnosed with FIPA and has a known AIP gene variant, you may be offered genetic testing to see if you also carry the variant. This can help determine your personal risk and guide decisions about screening and monitoring. You should discuss this with a genetic counsellor or specialist.
What is the typical treatment for pituitary adenomas in FIPA?
Treatment typically depends on the type, size, and symptoms caused by the adenoma. Options can include medications to control hormone levels, surgery to remove the tumour, or radiation therapy. A team of specialists will work together to create a personalised treatment plan.
How does FIPA affect children or young adults?
In FIPA, pituitary adenomas often develop at a younger age compared to sporadic cases, sometimes during childhood or adolescence. This can lead to specific issues like gigantism if growth hormone is overproduced before growth plates close. Early diagnosis and management are crucial for affected young individuals.
References
- Feingold KR, Adler RA, Ahmed SF. Acromegaly. 2000. PMID: 25905322
- Alband N, Korbonits M. Familial pituitary tumors. Handbook of clinical neurology. 2014. PMID: 25248598
- Feingold KR, Adler RA, Ahmed SF. Familial Isolated Pituitary Adenoma. 2000. PMID: 25905184
- de Lapiscina IM, Baquero C, Castaño L. Acromegaly and genetics. Vitamins and hormones. 2026. PMID: 41912295
- Tatsi C, Stratakis CA. The Genetics of Pituitary Adenomas. Journal of clinical medicine. 2019. PMID: 31877737
- Adam MP, Bick S, Mirzaa GM. AIP Familial Isolated Pituitary Adenomas. 1993. PMID: 22720333
- Bogusławska A, Korbonits M. Genetics of Acromegaly and Gigantism. Journal of clinical medicine. 2021. PMID: 33805450
- Rostomyan L, Potorac I, Beckers P. AIP mutations and gigantism. Annales d'endocrinologie. 2017. PMID: 28483363